Can We Have "Too Many Options?"

January 13th, 2009

Can We Have “Too Many Options?”

As part of our regular series “Antiretroviral Rounds” in AIDS Clinical Care, today we post a case of a highly treatment-experienced patient with dreaded “triple class” resistance — that is, resistance to NRTIs, NNRTIs, and PIs.

The good news now, of course, is that we have more than these three drug classes.

The tough part is choosing what to use, as often with so many new options we’re designing regimens that have not been extensively tested in prospective studies. (Or tested at all — for example, no patient in the maraviroc MOTIVATE studies received darunavir; today I’d suspect nearly every patient on this drug is on darunavir.)

We asked three highly-experienced HIV specialists what they’d do for a patient like this with “too many options” — raltegravir-naive, R5 tropic virus, susceptibility to both etravirine and darunavir — and perhaps not surprisingly, we got three different answers.

Further input to management of this case is welcome, of course.

Categories: Antiretroviral Rounds, HIV, Patient Care
Tags: darunavir, etravirine, HIV, maraviroc, raltegravir, resistance

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

War and Famine June 4, 2026

The prevalence of wasting among children in Gaza tracks with Israeli blockades on aid, but war may lead to famine even without such policies. How should starvation be prevented and treated in wartime?

The Unusual Suspects June 4, 2026

A 53-year-old man with Crohn’s disease and psoriasis presented with a 2-day history of headache, slurred speech, nausea, and vomiting. During the previous 2 weeks, he had had yellowing of the skin and eyes and dark urine.

Childhood Vaccine Hesitancy June 4, 2026

Vaccine hesitancy is often driven by safety concerns. Clinician recommendations, presumptive communication, and empathy improve uptake; maintaining trust supports future acceptance and community protection.

Sudan Virus Disease in Uganda, 2025 June 3, 2026

In January 2025, an outbreak of disease caused by Sudan virus, an ebolavirus, was identified in Uganda. Characteristics of this outbreak are described.

Intravenous Artesunate in Artemisinin-Resistant Severe Malaria in Uganda June 3, 2026

In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used.

HIV and ID Observations

An ongoing dialogue on HIV/AIDS, infectious diseases,
all matters medical, and some not so medical.

January 13th, 2009